Another inhibitor of FGFR 1, 2, and 3 is infigratinib, which showed promising clinical activity and manageable adverse effects in previously treated patients with locally advanced or metastatic CCA harboring FGFR2 gene fusions or rearrangements [137]. Here, FGFR2 is linked to cholangiocarcinoma.